Biotech Intelligence · Newsletter

Track CRISPR Deal Flow — First 200 Lock in $10/mo for Life

For biotech scouts, VC associates, and research coordinators who need signal, not noise.

What you're doing now: 2–4 hours a week screening bioRxiv abstracts and FDA filings manually — or paying a research analyst $500+/mo for coverage that's too broad for your deal focus. CRISPR Brief is the alternative that actually fits your workflow.

	Analyst ($500+/mo)	CRISPR Brief
Monthly cost	$500–2,000	$12 $10 — early-bird, first 200 lock it in
bioRxiv screening	General coverage, not CRISPR-specific	1 curated paper per issue with VC framing
FDA filing tracking	Extra cost or broad database access	1 targeted filing per issue with milestone watch
Competitive landscape notes	On request, billable hours	Built into every issue
Written for scouts & VCs	Reports written for general audiences	Framed for diligence and deal screening
Privacy	Requires firm affiliation disclosure	Pseudonymous — no institutional email required

What you get with every biweekly issue:

1 bioRxiv preprint — fully synthesized with competitive landscape and VC framing
1 FDA filing — clinical milestone and strategic relevance for your deal screen
1 company pipeline update — competitive positioning and key diligence flags
Priority question submission — request CRISPR coverage for your specific deal focus

Launch Offer

$10/mo $12/mo

Early-bird rate — locked for life

First 200 paid subscribers lock it in forever — never goes up.

$12$10/month

Early-bird locked for life · Cancel anytime · No credit card for free tier

Read Issue Zero Free → Or request manual delivery →

🔒 Pseudonymous author 📄 Issue Zero free ✉️ Cancel anytime

No personal brand required. The author's functional-genomics background is demonstrated through paper selection and analytical framing — not biography. Subscribers never need to know who runs CRISPR Brief.